10x Genomics, Inc. (Nasdaq: TXG), a Pleasanton, CA-based chief in single cell and spatial biology, is to amass Scale Biosciences, Inc., a pacesetter in progressive and scalable single cell evaluation.
The acquisition will additional broaden Chromium’s capabilities, broadening entry to single cell evaluation by making it accessible to researchers worldwide. This deal will assist a multi-year product roadmap for single cell innovation – one which goals to dramatically scale each the variety of cells and samples that may be analyzed, whereas preserving the multiomic information that researchers anticipate from 10x.
Scale Biosciences was based by a multidisciplinary staff of scientists and technologists with experience in subsequent era sequencing, genomics, and bioinformatics. Their work in combinatorial indexing and quantum barcoding represents a key development in scalable single cell evaluation. The corporate’s scientific founders, all of whom are becoming a member of 10x as advisors, are: Professor Garry Nolan at Stanford College, Professors Jay Shendureand Cole Trapnell at College of Washington and Frank Steemers. Scale is led by Giovanna Prout, President and CEO.
Led by Serge Saxonov, CEO, 10x Genomics is a life science expertise firm constructing merchandise to speed up the mastery of biology and advance human well being. Its built-in analysis options embody devices, consumables and software program for single cell and spatial biology, which assist tutorial and translational researchers and biopharmaceutical corporations perceive organic methods at a decision and scale that matches the complexity of biology.
10x will assist present Scale prospects with ongoing experiments, in addition to initiatives such because the 100 Million Cell Problem and the Billion Cells Undertaking. As well as, key Scale merchandise will stay available on the market.
FinSMEs
10/08/2025
